OBJECTIVE: To compare the use of an aromatase inhibitor (letrozole) with the use of clomiphene citrate (CC). DESIGN: Prospective randomized study. SETTING:An infertility clinic in a university hospital. PATIENT(S): Seventy-four consecutive infertile patients with polycystic ovary syndrome were recruited. Thirty-eight patients were randomized to the letrozole group (99 cycles), and the remaining patients were recruited to the CC group (95 cycles). INTERVENTION(S): The aromatase inhibitor letrozole (2.5 mg/d) and CC (100 mg/d) were administered orally on days 3-7 of menses. MAIN OUTCOME MEASURE(S): Number of follicles, endometrial thickness, E(2) levels on hCG day, and pregnancy rates among both groups. RESULT(S): Ovulation occurred in 65.7% (65/99) of letrozole cycles and in 74.7% (71/95) of CC cycles. The median (minimum-maximum) number of follicles sized >15 mm in diameter on the day of hCG administration were 1 (0-4) and 1 (0-5) in the letrozole and CC groups, respectively. On the day of hCG administration, median serum E(2) concentrations in the letrozole and CC groups were statistically significantly different: 189 pg/mL (18-1,581 pg/mL) and 386 pg/mL (27-6,190 pg/mL), respectively. The median serum E(2) concentrations per follicle sized >15 mm in diameter on the day of hCG also statistically significantly differed between the letrozole and CC groups: 160 pg/mL (18-808 pg/mL) and 281 pg/mL (27-2,615 pg/mL), respectively. The median endometrial thickness on the day of hCG did not significantly differ between the CC and letrozole groups; it was 8 mm. Pregnancy was achieved in nine cycles (9.1%) of the letrozole group and in seven cycles (7.4%) of the CC group, which also was not a statistically significant difference. CONCLUSION(S): The aromatase inhibitor letrozole may be an acceptable alternative to CC as an ovulation-induction drug in patients with PCOS.
RCT Entities:
OBJECTIVE: To compare the use of an aromatase inhibitor (letrozole) with the use of clomiphene citrate (CC). DESIGN: Prospective randomized study. SETTING: An infertility clinic in a university hospital. PATIENT(S): Seventy-four consecutive infertilepatients with polycystic ovary syndrome were recruited. Thirty-eight patients were randomized to the letrozole group (99 cycles), and the remaining patients were recruited to the CC group (95 cycles). INTERVENTION(S): The aromatase inhibitor letrozole (2.5 mg/d) and CC (100 mg/d) were administered orally on days 3-7 of menses. MAIN OUTCOME MEASURE(S): Number of follicles, endometrial thickness, E(2) levels on hCG day, and pregnancy rates among both groups. RESULT(S): Ovulation occurred in 65.7% (65/99) of letrozole cycles and in 74.7% (71/95) of CC cycles. The median (minimum-maximum) number of follicles sized >15 mm in diameter on the day of hCG administration were 1 (0-4) and 1 (0-5) in the letrozole and CC groups, respectively. On the day of hCG administration, median serum E(2) concentrations in the letrozole and CC groups were statistically significantly different: 189 pg/mL (18-1,581 pg/mL) and 386 pg/mL (27-6,190 pg/mL), respectively. The median serum E(2) concentrations per follicle sized >15 mm in diameter on the day of hCG also statistically significantly differed between the letrozole and CC groups: 160 pg/mL (18-808 pg/mL) and 281 pg/mL (27-2,615 pg/mL), respectively. The median endometrial thickness on the day of hCG did not significantly differ between the CC and letrozole groups; it was 8 mm. Pregnancy was achieved in nine cycles (9.1%) of the letrozole group and in seven cycles (7.4%) of the CC group, which also was not a statistically significant difference. CONCLUSION(S): The aromatase inhibitor letrozole may be an acceptable alternative to CC as an ovulation-induction drug in patients with PCOS.
Authors: Alexandra P Tsiami; Dimitrios G Goulis; Alexandros I Sotiriadis; Efstratios M Kolibianakis Journal: Hormones (Athens) Date: 2021-05-25 Impact factor: 2.885
Authors: Mohamed A Bedaiwy; Mahmoud A Abdelaleem; Mostafa Hussein; Noha Mousa; Lisa N Brunengraber; Robert F Casper Journal: Reprod Biol Endocrinol Date: 2011-06-21 Impact factor: 5.211